The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du MyƩlome (IFM) 2009-01 protocol.
Philippe Rodon
No relevant relationships to disclose
Cyrille Hulin
Honoraria - Celgene; Janssen-Ortho
Brigitte Pegourie
No relevant relationships to disclose
Mourad Tiab
No relevant relationships to disclose
Bruno Anglaret
No relevant relationships to disclose
Lotfi Benboubker
No relevant relationships to disclose
Henry Jardel
No relevant relationships to disclose
Olivier Decaux
Honoraria - Janssen-Ortho
Brigitte Kolb
No relevant relationships to disclose
Murielle Roussel
No relevant relationships to disclose
Laurent Garderet
No relevant relationships to disclose
Xavier Leleu
No relevant relationships to disclose
Olivier Fitoussi
No relevant relationships to disclose
Carine Chaleteix
No relevant relationships to disclose
Philippe Casassus
No relevant relationships to disclose
Pascal Lenain
No relevant relationships to disclose
Philippe Moreau
Consultant or Advisory Role - Janssen-Ortho; Millennium
Honoraria - Janssen-Ortho; Millennium
Marie-Odile Petillon
No relevant relationships to disclose
Claire Mathiot
No relevant relationships to disclose
Herve Avet-Loiseau
No relevant relationships to disclose